相关论文: Spatio-Temporal Graph Deep Learning with Stochasti…
Longitudinal neuroimaging is essential for modeling disease progression in Alzheimer's disease (AD), yet irregular sampling and missing visits pose substantial challenges for learning reliable temporal representations. To address this…
Identifying and utilising various biomarkers for tracking Alzheimer's disease (AD) progression have received many recent attentions and enable helping clinicians make the prompt decisions. Traditional progression models focus on extracting…
Alzheimer's disease (AD) is characterized by the progressive spread of pathology across brain networks, yet forecasting this cascade at the individual level remains challenging. We present a personalized graph-based dynamical model that…
Current neuroimaging techniques provide paths to investigate the structure and function of the brain in vivo and have made great advances in understanding Alzheimer's disease (AD). However, the group-level analyses prevalently used for…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disorder affecting millions of individuals today. The prognosis of the disease solely depends on treating symptoms as they arise and proper caregiving, as there are no current…
The uncertainty of clinical examinations frequently leads to irregular observation intervals in longitudinal imaging data, posing challenges for modeling disease progression.Most existing imaging-based disease prediction models operate in…
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder with substantial heterogeneity in progression and treatment response. Despite recent therapeutic advances, predictive models capable of accurately forecasting…
Alzheimer's disease (AD) is characterized by complex and largely unknown progression dynamics affecting the brain's morphology. Although the disease evolution spans decades, to date we cannot rely on long-term data to model the pathological…
Longitudinal assessment of brain atrophy, particularly in the hippocampus, is a well-studied biomarker for neurodegenerative diseases, such as Alzheimer's disease (AD). In clinical trials, estimation of brain progressive rates can be…
Alzheimer's disease (AD), a degenerative brain condition, can benefit from early prediction to slow its progression. As the disease progresses, patients typically undergo brain atrophy. Current prediction methods for Alzheimers disease…
Graph neural networks (GNNs) have been successfully applied to early mild cognitive impairment (EMCI) detection, with the usage of elaborately designed features constructed from blood oxygen level-dependent (BOLD) time series. However, few…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that predominantly affects the elderly population and currently has no cure. Magnetic Resonance Imaging (MRI), as a non-invasive imaging technique, is essential for the…
In order to find effective treatments for Alzheimer's disease (AD), we need to identify subjects at risk of AD as early as possible. To this end, recently developed disease progression models can be used to perform early diagnosis, as well…
Alzheimer's disease (AD) develops over a prolonged preclinical phase, during which neuropathological changes accumulate long before cognitive symptoms appear. Identifying cognitive functions affected at early stages is critical for the…
Alzheimer's disease is a progressive, neurodegenerative disorder that causes memory loss and cognitive decline. While there has been extensive research in applying deep learning models to Alzheimer's prediction tasks, these models remain…
Alzheimer's disease (AD) is known as one of the major causes of dementia and is characterized by slow progression over several years, with no treatments or available medicines. In this regard, there have been efforts to identify the risk of…
Alzheimer's disease (AD) progresses from asymptomatic changes to clinical symptoms, emphasizing the importance of early detection for proper treatment. Functional magnetic resonance imaging (fMRI), particularly dynamic functional network…
Neurodegeneration as measured through magnetic resonance imaging (MRI) is recognized as a potential biomarker for diagnosing Alzheimer's disease (AD), but is generally considered less specific than amyloid or tau based biomarkers. Due to a…
Alzheimer's disease (AD) is a degenerative brain disease impairing a person's ability to perform day to day activities. The clinical manifestations of Alzheimer's disease are characterized by heterogeneity in age, disease span, progression…
Volume change measures derived from longitudinal MRI (e.g. hippocampal atrophy) are a well-studied biomarker of disease progression in Alzheimer's Disease (AD) and are used in clinical trials to track the therapeutic efficacy of…